Compare AMPG & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPG | IMUX |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | 47 | 66 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.2M | 75.2M |
| IPO Year | N/A | 2013 |
| Metric | AMPG | IMUX |
|---|---|---|
| Price | $1.80 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.80 |
| AVG Volume (30 Days) | 372.8K | ★ 2.8M |
| Earning Date | 03-26-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $168.18 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.21 | $0.51 |
| 52 Week High | $4.89 | $1.51 |
| Indicator | AMPG | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 26.76 | 49.07 |
| Support Level | N/A | $1.07 |
| Resistance Level | $2.85 | $1.17 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 5.86 | 6.82 |
AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.